Search

As Head of Aboriginal Research Development at Telethon Kids, Glenn Pearson believes his work brings us closer to identifying the real and whole Australian story

More than 3,000 skin checks have been undertaken as part of a large clinical trial in WA’s Kimberley region aimed at halving the burden of skin sores in school-aged Aboriginal children.

The Institute has become one of the world’s leading Strep A hubs, with multiple teams working in the Institute’s END RHD Program, headed by Associate Professor Asha Bowen, working to understand how Strep A works and find better ways to prevent and control the diseases it causes.

Aboriginal health is everyone's business. The needs of Aboriginal and Torres Strait Islander families and kids is integrated into all relevant areas of our work. Improving the health and wellbeing of Aboriginal and Torres Strait Islander kids and families is an overarching priority for every team at The Kids.

Acute rheumatic fever is an immune-mediated condition triggered by Streptococcus pyogenes sore throat and possibly skin infection, with a substantial burden in resource-limited settings. Clinical decision rules (CDRs) are commonly used to guide antibiotic treatment of sore throat based on signs and symptoms, but their diagnostic accuracy varies by study and setting. This work aimed to assess the accuracy of multiple CDRs in Fiji to diagnose S. pyogenes sore throat.

The abundant skin commensal, Staphylococcus epidermidis, is the leading cause of late-onset sepsis (LOS) in preterm infants but rarely causes infections in term infants and adults. Staphylococcal virulence mechanisms and the role of the preterm immune responses in driving these life-threatening infections remain poorly understood.

House dust mites (HDMs) belong to the most potent indoor allergen sources worldwide and are associated with allergic manifestations in the respiratory tract.

Debbie Susan Palmer Prescott BSc BND PhD MBBS BMedSci PhD FRACP Head, Nutrition in Early Life Honorary Research Fellow debbie.palmer@uwa.edu.au

Invasive aspergillosis (IA) in haematology/oncology patients presents as primary infection or breakthrough infection, which can become refractory to antifungal treatment and has a high associated mortality. Other emerging patient risk groups include patients in the intensive care setting with severe respiratory viral infections, including COVID-19.

This article introduces the fourth update of the Australian and New Zealand consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting. These guidelines are comprised of nine articles as presented in this special issue of the Internal Medicine Journal. This introductory chapter outlines the rationale for the current update and the steps taken to ensure implementability in local settings.